טוען...
Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
INTRODUCTION: Regorafenib is an oral multikinase inhibitor for the treatment of metastatic colorectal cancer (mCRC). The clinical factors that may affect adherence to regorafenib remain unclear. The aim of this study was to evaluate adherence to regorafenib with mCRC and to identify factors that mig...
שמור ב:
| הוצא לאור ב: | Patient Prefer Adherence |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800560/ https://ncbi.nlm.nih.gov/pubmed/31686792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S217835 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|